Alzai Health (FRA:H2F) Other Operating Expense: €0.06 Mil (TTM As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:H2F Alzai Health Corp FRA:H2F
9 GF Score
Price €0.17
! 1 Warning Sign
View Full Analysis

What is Alzai Health Other Operating Expense?

Alzai Health FRA:H2F -1.62% 9 Other Operating Expense is €0.06 Mil as of Jan. 2026. GuruFocus rates FRA:H2F with a GF Score™ of 9/100. The stock has 1 warning sign investors should review.

Alzai Health's Other Operating Expense for the three months ended in Jan. 2026 was €0.01 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jan. 2026 was €0.06 Mil.

Alzai Health's quarterly Other Operating Expense increased from Jul. 2025 (€0.02 Mil) to Oct. 2025 (€0.03 Mil) but then declined from Oct. 2025 (€0.03 Mil) to Jan. 2026 (€0.01 Mil).

Alzai Health Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Alzai Health's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzai Health Other Operating Expense Chart

Alzai Health Annual Data
Trend Apr25
Other Operating Expense
0.00

Alzai Health Quarterly Data
Jan25 Apr25 Jul25 Oct25 Jan26
Other Operating Expense -0.00 0.00 0.02 0.03 0.01
FRA:H2F
9GF Score
Alzai Health Corp FRA:H2F
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alzai Health Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of €0.06 Mil mean?
Alzai Health (FRA:H2F) has a Other Operating Expense of €0.06 Mil as of Jan. 2026. Other operating expenses that a company records on its income statement. View historical data on Alzai Health and its competitors.
Is Alzai Health's Other Operating Expense too high?
Alzai Health's current Other Operating Expense is €0.06 Mil. Overall, Alzai Health has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Alzai Health's Other Operating Expense compare to VRTX and REGN?
Alzai Health's Other Operating Expense of €0.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Alzai Health and its competitors. Alzai Health's current Other Operating Expense is €0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzai Health stock overvalued right now?
Alzai Health (FRA:H2F) has a current Other Operating Expense of €0.06 Mil. The current Other Operating Expense is €0.06 Mil. Alzai Health's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Alzai Health (FRA:H2F), the current Other Operating Expense is €0.06 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alzai Health Business Description

Other Exchanges ALZI:Canada
Address 22 Adelaide Street West, Suite 3400, Toronto, ON, CAN, M5H 4E3
Alzai Health Corp is a healthcare company focused on comprehensive health solutions. It is an AI-driven Alzheimer's disease risk screening platform, enabling disease prevention and early disease diagnosis to improve patient outcomes. The company uses low-cost, non-invasive, pre-existing biomarker data present in nearly all Electronic Medical Records of the relevant age demographic. It aims to address the unmet need in Alzheimer's screening, enabling early detection and mitigation driving to diagnosis, therapy or prevention.
9GF Score

Get the complete analysis for FRA:H2F

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.17
Price